^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

STK-009/SYNCAR-001

i
Other names: STK-009/SYNCAR-001, STK 009/SYNCAR 001, STK009/SYNCAR001
Associations
Company:
Synthekine
Drug class:
CD19-targeted CAR-T immunotherapy, IL-2 stimulant
Related drugs:
Associations
2ms
Enrollment open • CAR T-Cell Therapy
|
STK-009/SYNCAR-001
3ms
New P1 trial • CAR T-Cell Therapy
|
STK-009/SYNCAR-001
9ms
Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
11ms
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
12ms
Trial initiation date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
1year
Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models (SITC 2023)
Importantly, STK-009 induced the expression of cytotoxic machinery, pro-survival, and proliferative genes in tumor-infiltrating SYNCAR-002 (figure 3). Conclusions These findings validate that the orthogonal IL-2 platform has the potential to improve the efficacy and durability of CAR T therapy for solid tumor targets such as GPC3 by selectively expanding CAR-T cells in vivo and activating CAR-T cells in a hostile tumor microenvironment.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • GPC3 (Glypican 3) • IL2 (Interleukin 2)
|
CD19 expression • GPC3 expression
|
STK-009/SYNCAR-001
over1year
A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062) (AACR 2023)
Secondary endpoints include assessments of response, pharmacokinetics, and immunogenicity. Exploratory endpoints include assessment of immune cell populations, and relevant gene/protein expression, as well as persistence, phenotype, and functionality of SYNCAR-001 in the peripheral blood and/or bone marrow in response to STK-009.
Clinical • P1 data • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL2 (Interleukin 2)
|
CD19 expression
|
STK-009/SYNCAR-001
almost2years
New P1 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
over2years
Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models (AACR 2022)
STK-009 treatment resulted in significant expansion of SYNCAR-002 and drove infiltration of SYNCAR-002 into tumors. STK-009 treatment also induced intratumoral granzyme B+ and IFN-γ+ production by SYNCAR-002 indicating activation of effector T cell function.These findings validate that the orthogonal IL-2 platform has the potential to improve the efficacy and durability of CAR T therapy for solid tumor targets such as GPC3 by selectively expanding CAR-T cells in vivo, driving CAR-T cells into the tumor, and activating CAR-T cells in the tumor microenvironment.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • GZMB (Granzyme B)
|
CD19 expression • GPC3 expression • GPC3 overexpression
|
STK-009/SYNCAR-001
over3years
[VIRTUAL] OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumor efficacy by driving T cell expansion and fitness (AACR 2021)
Pharmacokinetic analysis of STK-009 shows stable exposure with minimal clearance, demonstrating the selectivity of STK-009.These findings validate an orthogonal platform that selectively drives potent T cell effector functions of engineered cells without the toxicities mediated by NK cells or non-tumor specific T cells associated with high dose IL-2 therapy. These results demonstrate the ability of this orthogonal platform to improve the efficacy and durability of CARs.
Clinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • IL2 (Interleukin 2)
|
CD19 expression
|
STK-009/SYNCAR-001